CISIV believes that understanding how medicines work in normal use is fundamentally different from developing them through clinical trials.

Their purpose built platform, Baseline Plus, collects data and analytics from real-world medical research and provides them to pharma companies and clinical research organisations.

The platform provides a set of web-based tools that enable easy data collection and efficient management of data quality across the diverse range of real-world studies.

We invested in CISIV in March 2019. 

Investment rationale

The collection and management of real world data is a global market driven by the need to increase the external validity of drug trials, as opposed to clinical trials, which remove external factors by using highly controlled conditions. Real world research is seen as one of the fastest growing sectors of medical research, with 54% of life sciences companies surveyed in 2018 by Deloitte actively investing in real world evidence programmes.